Rebecca A Harrington1, Li-Ching Lee2, Rosa M Crum3, Andrew W Zimmerman4, Irva Hertz-Picciotto5. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and rharring@jhsph.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and. 3. Departments of Epidemiology, Psychiatry, and Mental Health, Johns Hopkins Medical Institutions, Baltimore, Maryland; 4. Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts; and. 5. Department of Public Health Sciences and the MIND Institute, University of California, Davis, Davis, California.
Abstract
OBJECTIVE: To examine associations between prenatal use of selective serotonin reuptake inhibitors (SSRIs) and the odds of autism spectrum disorders (ASDs) and other developmental delays (DDs). METHODS: A total of 966 mother-child pairs were evaluated (492 ASD, 154 DD, 320 typical development [TD]) from the Childhood Autism Risks from Genetics and the Environment (CHARGE) Study, a population-based case-control study. Standardized measures confirmed developmental status. Interviews with biological mothers ascertained prenatal SSRI use, maternal mental health history, and sociodemographic information. RESULTS: Overall, prevalence of prenatal SSRI exposure was lowest in TD children (3.4%) but did not differ significantly from ASD (5.9%) or DD (5.2%) children. Among boys, prenatal SSRI exposure was nearly 3 times as likely in children with ASD relative to TD (adjusted odds ratio [OR]: 2.91; 95% confidence interval [CI]: 1.07-7.93); the strongest association occurred with first-trimester exposure (OR: 3.22; 95% CI: 1.17-8.84). Exposure was also elevated among boys with DD (OR: 3.39; 95% CI: 0.98-11.75) and was strongest in the third trimester (OR: 4.98; 95% CI: 1.20-20.62). Findings were similar among mothers with an anxiety or mood disorder history. CONCLUSIONS: In boys, prenatal exposure to SSRIs may increase susceptibility to ASD or DD. Findings from published studies on SSRIs and ASD continues to be inconsistent. Potential recall bias and residual confounding by indication are concerns. Larger samples are needed to replicate DD results. Because maternal depression itself carries risks for the fetus, the benefits of prenatal SSRI use should be carefully weighed against potential harms.
OBJECTIVE: To examine associations between prenatal use of selective serotonin reuptake inhibitors (SSRIs) and the odds of autism spectrum disorders (ASDs) and other developmental delays (DDs). METHODS: A total of 966 mother-child pairs were evaluated (492 ASD, 154 DD, 320 typical development [TD]) from the Childhood Autism Risks from Genetics and the Environment (CHARGE) Study, a population-based case-control study. Standardized measures confirmed developmental status. Interviews with biological mothers ascertained prenatal SSRI use, maternal mental health history, and sociodemographic information. RESULTS: Overall, prevalence of prenatal SSRI exposure was lowest in TD children (3.4%) but did not differ significantly from ASD (5.9%) or DD (5.2%) children. Among boys, prenatal SSRI exposure was nearly 3 times as likely in children with ASD relative to TD (adjusted odds ratio [OR]: 2.91; 95% confidence interval [CI]: 1.07-7.93); the strongest association occurred with first-trimester exposure (OR: 3.22; 95% CI: 1.17-8.84). Exposure was also elevated among boys with DD (OR: 3.39; 95% CI: 0.98-11.75) and was strongest in the third trimester (OR: 4.98; 95% CI: 1.20-20.62). Findings were similar among mothers with an anxiety or mood disorder history. CONCLUSIONS: In boys, prenatal exposure to SSRIs may increase susceptibility to ASD or DD. Findings from published studies on SSRIs and ASD continues to be inconsistent. Potential recall bias and residual confounding by indication are concerns. Larger samples are needed to replicate DD results. Because maternal depression itself carries risks for the fetus, the benefits of prenatal SSRI use should be carefully weighed against potential harms.
Authors: Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto Journal: Autism Res Date: 2013-03-14 Impact factor: 5.216
Authors: Lauren C Shuffrey; Stephen J Guter; Shannon Delaney; Suma Jacob; George M Anderson; James S Sutcliffe; Edwin H Cook; Jeremy Veenstra-VanderWeele Journal: Autism Res Date: 2017-04-12 Impact factor: 5.216
Authors: Xiaoming Zhou; Jordan Y-F Lu; Ryan D Darling; Kimberly L Simpson; Xiaoqing Zhu; Fang Wang; Liping Yu; Xinde Sun; Michael M Merzenich; Rick C S Lin Journal: Proc Natl Acad Sci U S A Date: 2015-02-02 Impact factor: 11.205
Authors: Alexander Viktorin; Rudolf Uher; Alexander Kolevzon; Abraham Reichenberg; Stephen Z Levine; Sven Sandin Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596
Authors: Cécile Gurnot; Ignacio Martin-Subero; Sarah M Mah; Whitney Weikum; Sarah J Goodman; Ursula Brain; Janet F Werker; Michael S Kobor; Manel Esteller; Tim F Oberlander; Takao K Hensch Journal: Epigenetics Date: 2015-04-18 Impact factor: 4.528
Authors: Cheryl K Walker; Paula Krakowiak; Alice Baker; Robin L Hansen; Sally Ozonoff; Irva Hertz-Picciotto Journal: JAMA Pediatr Date: 2015-02 Impact factor: 16.193